ArticleCureus2025
Intertumoral Heterogeneity in Multifocal Breast Cancer Mimicking a Collision Tumor on Imaging: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer exhibits heterogeneity characterized by intertumor heterogeneity, where distinct lesions present different subtypes, and intratumor heterogeneity, where a single tumor evolves over time. We present a unique case of synchronous, adjacent multifocal breast cancers demonstrating histological findings of distinct molecular subtypes. A 72-year-old woman with a history of ovarian cancer and a family history of breast cancer presented with a right breast lump. Imaging showed two contiguous but distinct lesions. Core needle biopsy identified invasive ductal carcinoma. Immunohistochemistry revealed luminal B and luminal B/human epidermal growth factor receptor 2 (HER2)-positive subtypes. Total mastectomy and sentinel lymph node biopsy were performed, and pathology confirmed two partially fused tumors separated by fibrous stroma. The HER2-positive component demonstrated higher proliferative activity and nuclear grade. Postoperatively, the patient received chemotherapy, anti-HER2 therapy, and remains disease-free on endocrine therapy. This case highlights a rare breast cancer presentation with identical histology but different molecular subtypes mimicking a collision tumor on imaging. It underscores the clinical relevance of tumor heterogeneity and the importance of combining imaging, pathology, and molecular profiling for accurate diagnosis and tailored treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.